SUBSCRIBE

Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

Soliris first drug recommended through NICE's specialised tech unit

NICE’s highly specialised technologies programme has recommended Alexion’s mAb Soliris, despite a lack of justification for the £340,000 ($513,000) price per patient.

Alexion's Soliris recommended by NICE in England and Wales

US dollar prompts ThermoFisher to predict flat revs in 2015 and move reagents to Lithuania

ThermoFisher has forecast flat sales and earnings in 2015, warning that weaker currencies in key markets will offset higher biopharma spending.

Valeant eyes up personalised meds market with $300m Provenge bid

Valeant is set to buy Dendreon’s prostate cancer drug Provenge as an economic way to enter the personalised oncology market.

News in brief

BioPharma-Reporter.com book competition: final entries

Today is the last chance for readers of BioPharma-Reporter.com to enter our giveaway for a chance to win Eula Biss’s award-winning book On Immunity.

Neupogen competition a blemish on Amgen's 'outstanding' 2014 says firm

Amgen has benefited from enhanced regulatory discussions surrounding biosimilars, the firm says, as it develops a pipeline of nine products alongside its own biologics.

Sartorius: US fully embracing single-use as bioprocess unit leads 13% growth

The US has caught up with Europe in adopting single-use technologies, says Sartorius which reported a 32% growth in sales for the region in 2014.

Spotlight

Teva: More biomanufacturing space needed to tap biologics

Teva: More biomanufacturing space needed to tap biologics opportunities

Teva must invest in its biomanufacturing network as the firm’s biologics aspirations grow beyond biosimilars, CEO Erez Vigodman...

Novozymes predicts half-life boost for pharma business, but lets long term rev forecast slide on oil prices

Novozymes predicts half-life boost for pharma business, but lets long term rev forecast slide on oil prices

Novozymes finished 2014 with higher pharma revenues thanks in part to GSK's adoption of its albumin half-life...

Sanofi selects B-I to manufacture growing monoclonal antibody pipeline

Sanofi selects B-I to manufacture growing monoclonal antibody portfolio

Sanofi has selected Boehringer-Ingelheim to manufacture monoclonal antibodies in an agreement that extends to the French drugmaker's...

Exclusive extract: 'On Immunity: An Inoculation' by Eula Biss

Exclusive extract: 'On Immunity: An Inoculation' by Eula Biss

In an exclusive extract from her recent book On Immunity: An Innoculation, author Eula Biss describes her...

Probodies perfect! CytomX raises $20m funding led by Pfizer

Probodies perfect! CytomX raises $20m funding led by Pfizer

The $20m funding led by Pfizer Venture Investments will help advance a platform to make Probodies which...

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...